All In Biotech

Drug Trial Radar · NCT03384823

A Study of EDP-938 in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study of Orally Administered EDP-938 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (SAD), Multiple Ascending Doses (MAD) and the Effect of Food on EDP-938 Pharmacokinetics in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Oct 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

90

Actual

Start

Dec 7, 2017

Primary completion

Jul 3, 2018

Study completion Jul 3, 2018

Sponsor

Lead sponsor
Enanta Pharmaceuticals, IncIndustry
Sponsor type
Industry
Collaborators
Pharmaceutical Research Associates
First posted
Dec 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This randomized, double-blind, placebo-controlled study will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-938 in healthy adult subjects

Conditions

  • RSV Infection

Interventions

  • EDP-938Drug

    Subjects will receive either a single dose of EDP-938 on Day 1 only (SAD) or a single dose of EDP-938 starting on Day 1 through Day 7 (MAD).

  • PlaceboDrug

    placebo to match EDP-938

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety measured by adverse events, physical exams, vital signs, 12-lead electrocardiograms (ECGs) and clinical lab results (including chemistry, hematology, and urinalysis).Time frame: Up to 8 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaceutical Research Associates, Inc.,

    Lenexa, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.